Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.
Kidney allograft fibrosis results from a reactive process mediated by humoral and cellular events and the activation of transforming growth factor beta1. It is a process that involves both parenchymal and graft infiltrating cells and can lead to organ failure if injury persists or if the response to injury is excessive. In this review, we will address the role of preventive and therapeutic strategies that target kidney allograft fibrogenesis. We conclude that in addition to preventive strategies, therapies based on bone morphogenetic protein 7, hepatocyte growth factor, connective tissue growth factor, and pirfenidone have shown promising results in preclinical studies. Clinical trials are needed to examine the effect of these therapies on long-term outcomes.
Djamali
Arjang
A
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53793, USA.
Samaniego
Millie
M
D018925:Chemokines / Q000502:physiology; D005355:Fibrosis / Q000517:prevention & control*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D056724:Immunity, Humoral; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology*; D010671:Phenylurea Compounds / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000502:physiology; D020123:Sirolimus / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000502:physiology*
D018925:Chemokines; D007166:Immunosuppressive Agents; D010671:Phenylurea Compounds; D010880:Piperidines; D019707:Receptors, Chemokine; D016212:Transforming Growth Factor beta; C411885:BX 471; D020123:Sirolimus